Cerevel Therapeutics Holdings, Inc. CERE shares are trading higher Thursday after AbbVie, Inc. ABBV announced it will acquire the company for a total equity value of approximately $8.7 billion.
What To Know:
AbbVie announced that it will acquire Cerevel Therapeutics after the market close on Wednesday. AbbVie will acquire all outstanding shares of Cerevel for $45 per share in cash, with the transaction anticipated to close in the middle of 2024.
On Thursday, Cantor Fitzgerald analyst Charles Duncan downgraded Cerevel Therapeutics from Overweight to Neutral and raised the price target from $38 to $45. Piper Sandler analyst David Amsellem downgraded Cerevel Therapeutics from Overweight to Neutral and raised the price target from $33 to $45.
CERE shares are climbing on heavy volume with more than 15 million shares traded in the session, compared to the stock's 100-day average volume of just under 1.2 million shares.
Related News: What's Going On With Robinhood Markets Stock?
CERE Price Action: According to Benzinga Pro, Cerevel Therapeutics shares are up by more than 12% at $41.53 at the time of publication.
Image: Alexandra Koch from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
